Physician profile
Erick Lu
NPI 1417278359
$5,696.85
in general payments reported to CMS, 2019-2025
30 companies · $1,624 in 2025
The $1,624 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $76.99 · 2021: $200 · 2022: $810 · 2023: $593 · 2024: $1,422 · 2025: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.00 |
| Education | $150.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,209.48 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,188.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $555.99 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Actelion Pharmaceuticals US, INC. | $441.51 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $359.57 | 2019-2025 | Dupixent |
| Genzyme Corporation | $280.13 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $264.73 | 2022-2025 | Zerbaxa, Winrevair, Dificid |
| Philips North America LLC | $193.02 | 2019-2023 | |
| Verona Pharma, INC. | $156.55 | 2025 | Ohtuvayre |
| Abiomed | $125.00 | 2024 | Impella |
| United Therapeutics Corporation | $89.55 | 2024-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $83.21 | 2020-2024 | Wakix |
| Grifols USA, LLC | $73.83 | 2019-2021 | |
| Gilead Sciences, INC. | $71.87 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $70.99 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $70.07 | 2019-2023 | Arikayce |
| Novartis Pharmaceuticals Corporation | $64.89 | 2019-2022 | |
| Viatris Specialty LLC | $61.57 | 2025 | Yupelri |
| Mylan Specialty L.P. | $52.66 | 2023-2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $47.65 | 2024 | Nuzyra |
| Portola Pharmaceuticals, LLC | $42.47 | 2019 | |
| Shionogi INC | $31.98 | 2024 | Fetroja |
| Genentech USA, INC. | $31.39 | 2019-2023 | Xolair |
| Advanced Respiratory, INC | $27.77 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.26 | 2019 | |
| Sanofi Pasteur INC. | $19.62 | 2024 | |
| Amgen INC. | $18.14 | 2022 | |
| Baxter Healthcare | $14.38 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Pfizer INC. | $13.85 | 2021 | |
| Phadia US INC. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.